<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03057548</url>
  </required_header>
  <id_info>
    <org_study_id>PIVotal-01</org_study_id>
    <nct_id>NCT03057548</nct_id>
  </id_info>
  <brief_title>Comparison of Pulmonary Vein Ablation With or Without Left Atrial Posterior Wall Ablation for Persistent AF (PIVoTAL)</brief_title>
  <acronym>PIVoTAL</acronym>
  <official_title>Left Atrial Posterior Wall Isolation in Conjunction With Pulmonary Vein Isolation for Treatment of Persistent Atrial Fibrillation (PIVoTAL) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arash Aryana, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sacramento EP Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study it to learn whether pulmonary vein isolation (PVI) along with&#xD;
      ablation of the posterior left atrial wall (PLAW) will reduce the likelihood of atrial&#xD;
      fibrillation (AF) recurrence in patients with persistent or long-standing persistent AF one&#xD;
      year after an ablation procedure in comparison to a PVI ablation procedure, alone.&#xD;
&#xD;
      The investigator hypothesizes that the combination of PVI plus PLAW isolation will result in&#xD;
      a reduction in recurrence of atrial arrhythmias at one year after ablation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with persistent or long-standing persistent atrial fibrillation will be enrolled in&#xD;
      this multi-center, randomized, prospective, single-blinded study. All patients are required&#xD;
      to be in atrial fibrillation (AF) on the day of the ablation procedure. After ablation&#xD;
      (isolation) of the pulmonary veins (PVI) is complete, and while still in the&#xD;
      electrophysiology lab, all patients are randomized to either PVI, alone [Group 1] or the&#xD;
      combination of PVI plus ablation of the posterior left atrial wall (PLAW) [Group 2]. For&#xD;
      those patients randomized to PVI, their ablation procedure is complete at this time. For&#xD;
      those patients randomized to PVI plus PLAW, they will have the additional ablation to the&#xD;
      posterior left atrial wall performed.&#xD;
&#xD;
      All study patients have the same follow-up after their ablation procedure: clinic visits at&#xD;
      3, 6, and 13 months; a heart event monitor is worn for 7-14 days before these visits. An&#xD;
      echocardiogram is done at 4-6 months after the ablation procedure. Blood thinners are usually&#xD;
      recommended for three months after the ablation procedure and then the need for continued use&#xD;
      of blood thinners will be based on individual patient's medical history, stroke risk and the&#xD;
      judgement of their study doctor. Information about patient's medical history, heart&#xD;
      arrhythmias, and atrial fibrillation will be collected during the study. This information&#xD;
      will be analyzed as part of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 24, 2017</start_date>
  <completion_date type="Actual">May 31, 2020</completion_date>
  <primary_completion_date type="Actual">May 13, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1-year freedom from recurrent atrial arrhythmias</measure>
    <time_frame>One year</time_frame>
    <description>Number of patients with recurrent atrial arrhythmias following catheter ablation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall complication rate</measure>
    <time_frame>During follow-up, assessed for an estimated total of one year.</time_frame>
    <description>The type and frequency of complications following catheter ablation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Atrial Fibrillation Chronic</condition>
  <condition>Persistent Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Pulmonary Vein Isolation (PVI)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cryoablation only of Pulmonary Veins&#xD;
or&#xD;
Radiofrequency ablation only of Pulmonary Veins&#xD;
Pulmonary Vein Isolation (PVI) alone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PVI &amp; Posterior Left Atrial Ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cryoablation of Pulmonary Veins plus RF ablation of Posterior Left Atrial Wall&#xD;
or&#xD;
Radiofrequency ablation of Pulmonary Veins plus RF ablation of Posterior Left Atrial Wall&#xD;
PVI ablation plus ablation of the Posterior Left Atrial Wall (PLAW)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cryo or RF Ablation only of Pulmonary Veins</intervention_name>
    <description>Artic Front Advance Cardiac Cryoabltion System used to ablate the Pulmonary Veins&#xD;
OR&#xD;
FDA Approved RF Ablation Catheter used to ablate the Pulmonary Veins.&#xD;
Ablation of the Pulmonary Veins alone</description>
    <arm_group_label>Pulmonary Vein Isolation (PVI)</arm_group_label>
    <other_name>Artic Front Advance Cardiac Cryoablation System</other_name>
    <other_name>FDA Approved Radiofrequency Ablation Catheter</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cryo or RF Ablation of Pulmonary Veins plus Ablation of the PLAW</intervention_name>
    <description>Cryoablation of the Pulmonary Veins plus RF Ablation of the PLAW&#xD;
OR&#xD;
RF Ablation of the Pulmonary Veins plus RF Ablation of the PLAW&#xD;
Ablation of the Pulmonary Veins plus RF ablation of the Posterior Left Atrial Wall (PLAW)</description>
    <arm_group_label>PVI &amp; Posterior Left Atrial Ablation</arm_group_label>
    <other_name>Cryoablation of Pulmonary Veins plus RF Ablation of PLAW</other_name>
    <other_name>RF Ablation of Pulmonary Veins plus RF Ablation of PLAW</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females with an age &gt;18 years undergoing a first-time catheter ablation of&#xD;
             AF; prior ablation of a right atrial cardiac arrhythmia (i.e., typical right atrial&#xD;
             flutter) is permitted&#xD;
&#xD;
          -  All patients must understand the requirements of the study and be willing to comply&#xD;
             with the post-study follow-up requirements&#xD;
&#xD;
          -  Patients must be in AF on the day of the procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any reversible cause of AF (post-operative, thyroid disorder, etc)&#xD;
&#xD;
          -  Patients with cerebral ischemic events (stroke or transient ischemic attack),&#xD;
             myocardial infarction or unstable angina in the previous 2 months&#xD;
&#xD;
          -  Patients with any corrected or uncorrected congenital heart disease&#xD;
&#xD;
          -  Patients with a history of hypertrophic cardiomyopathy&#xD;
&#xD;
          -  Patients with cardiomyopathy and a left ventricular ejection fraction &lt;35%&#xD;
&#xD;
          -  Congestive heart failure, class IV&#xD;
&#xD;
          -  Women who are known to be pregnant or have had a positive Î²-HCG test 7 days prior to&#xD;
             procedure&#xD;
&#xD;
          -  Patients whose life expectancy is &lt;1 year&#xD;
&#xD;
          -  History of left-sided left atrial ablation (catheter or surgically-based)&#xD;
&#xD;
          -  Mental impairment precluding the patient from providing informed consent or completing&#xD;
             appropriate follow-up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arash Aryana, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mercy General Hospital and Dignity Health Heart and Vascular Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mercy General Hospital and Dignity Health Heart and Vascular Institute</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Center, Japan Red Cross Yokohama-city Bay Hospital</name>
      <address>
        <city>Yokohama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 8, 2017</study_first_submitted>
  <study_first_submitted_qc>February 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2017</study_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sacramento EP Research</investigator_affiliation>
    <investigator_full_name>Arash Aryana, MD</investigator_full_name>
    <investigator_title>Cardiac Electrophysiologist / Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Long-Standing Atrial Fibrillation</keyword>
  <keyword>Posterior Left Atrial Wall Ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

